A more specific activity inhibition targeted exclusively to MMP-9, particularly in colon cancer, where this MMPI might act in situ, may be of significant potential to anticancer and anti-inflammatory approaches in the gastrointestinal diseases. Here, MMP9 is linked to malignant colon neoplasm.